Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn

 
• By Sue Sutter
  
Marbles
The FDA and Lilly disagree on the number and type of "amino acids" that would make retatrutide a biological product. • Source: Shutterstock

More from Legal & IP

More from Pink Sheet